[STUDY_ID_REMOVED]  
Protocol (May 2014) and Statistical Analysis Plan (7 April 2021) 
A Phase 2, Multicenter, Open Label Study to Evaluate the Efficacy and Safety of OK -[ADDRESS_56828] a n  
 
 
Pr ot oc ol O K -4 3 2 -0 0 3 -O P E N  
Pr otara T hera pe utics , I nc. 
 
 
A M U L TI C E N T E R, O P E N -L A B E L  S T U D Y  T O E V A L U A T E  T H E E F FI C A C Y A N D 
S A F E T Y  O F O K -4 3 2 I M M U N O T H E R A P Y I N  I N DI VI D U A L S WI T H L Y M P H A TI C 
M A L F O R M A TI O N S  
 
 
P hase 2  E x pa nsi o n  
 
 
 
Pr ot oc ol  V ersi o n D ate d : M A Y 2 0 1 4  
 
 
 
 
 
 
Pre p are d 
 
 
 
 
 
 
 
Versi o n:  Fi nal  
 
D ate:  A pril [ADDRESS_56829] a n  
 
Pr ot oc ol O K -4 3 2 -0 0 3 -O P E N  
Pr otara T hera pe utics , I nc. 
 
 
A M U L TI C E N T E R, O P E N -L A B E L S T U D Y  T O E V A L U A T E T H E E F FI C A C Y A N D 
S A F E T Y O F O K -4 3 2 I M M U N O T H E R A P Y I N  I N DI VI D U A L S WI T H L Y M P H A TI C 
M A L F O R M A TI O N S  
 
 
P hase 2 E x pa nsi o n  
 
 
Pr ot oc ol V ersi o n D ate d :  M A Y 2 0 1 4  
 
 
T his Statistical A nal ysis Pla n has bee n re vie we d a n d a p pr o ve d b y:  
                    
 O K -[ADDRESS_56830] ure  ................................................................................................... 7  
4 S T U D Y E N D P OI N T S  .................................................................................................................................. 1 0  
4. 1 Pri mar y Efficac y E n d p oi nt(s)  ............................................................................................................. [ADDRESS_56831] u d y B aseli ne  ................................................................................................. 1 3  
7. 1. 3 Deri vi n g Res p o nse Data  ....................................................................................................... 1 3  
7. 1. 4 Ha n dli n g of M ulti ple O bser vati o ns  ...................................................................................... 1 4  
7. 1. 5 Visit Ma p pi n g d ue t o C ha n ge i n Pr ot oc ol  ............................................................................ 1 4  
7. 1. 6 Ha n dli n g of Missi n g or P artial Dates  ................................................................................... 1 4  
7. 1. 7 Ha n dli n g of Missi n g Efficac y Data  ...................................................................................... 1 5  
7. 2 Efficac y A nal yses  ............................................................................................................................... 1 5  
7. 2. 1 A nal yses of Pri mar y E n d p oi nt(s)  ......................................................................................... [ADDRESS_56832] f or i ntrac ystic 
a d mi nistrati o n f or t he treat me nt of l y m p hatic m alf or mati o ns ( L Ms) i n pe diatric a n d a d ult 
s u bjects. TA R A -0 0 2  is a l y o p hiliz e d bi ol o gical pr e parati o n f or i njecti o n c o ntai ni n g 
atte n uate d cells of Stre pt oc occ us p y o ge nes ( A gr o u p, t y pe 3) S u strai n treat e d wit h 
be nz yl pe nicilli n.  T he c h aracteristics of T A R A -0 0 2 are i nte n de d t o b e c o m p ara ble t o O K -4 3 2 
( ma n ufacture d b y C h u gai P har mace uticals) w hic h is c urre ntl y a p pr o ve d i n Ja pa n a n d T ai wa n 
f or use as tr eat me nt f or L Ms. T heref ore, n o ncli nic al a n d cli nical st u dies wit h O K -[ADDRESS_56833] u g a p plicati o n (IN D) was o pe n e d b y  
at t he U ni versit y of I o w a  t o e val uate t he p ote ntial safet y a n d effic ac y of O K-[ADDRESS_56834] u d y  ( O K-4 3 2 -0 0 2 -R A N D) , all ne w  s u bjects w h o prese nte d wit h a n 
L M a n d were eli gi ble f or treat me nt were treate d u n der a n o pe n -la bel pr ot o c ol f or c o nti n ue d 
access t o O K-[ADDRESS_56835] u d y ( O K-4 3 2 -0 0 3 -O P E N)  e nr olle d patie nts 
bet wee n S e pte m b er [ADDRESS_56836] u d y is t o pr o vi de  i m m u n osti m ula nt O K -4 3 2 t o s u bjects wit h 
macr oc y stic or mi x e d ( > 5 0 % macr oc ystic) L Ms a n d i n vesti gate  t he effi cac y a n d s afet y of  
O K -[ADDRESS_56837] 
eli gi ble s u bjects w ere b et wee n 6 m o nt hs a n d 1 8 years of a ge wit h a L M t hat was macr oc ystic 
or mi x e d ( > 5 0 % macr oc ystic) . C lassificati o n was deter mi ne d ra di o gra p hic all y b y c o m p ute d 
t o m o gra p h y ( C T) or ma g netic res o na n ce i ma gi n g ( M RI) sca ns b y me as uri n g t he v ol u me of 
all c ysts. Macr oc ystic L M s were d efi ne d as c ystic s paces ≥ 2. 0 ml ( 2 c m × 1 c m × 1c m) . L M 
wit h b ot h macr oc ystic a n d micr oc ystic  ( m ulti ple c ysts, eac h less t ha n 2 cc i n v ol u me) lesi o ns 
were d esi g n ate d mi x e d L M.  
S u bject s recei v e d O K-[ADDRESS_56838] at eac h sessi o n was  0. 2 m g at a 
c o nce ntr ati o n of 0. 0 1 -0. 0 5 m g/ ml . T his c o nce ntr ati o n  was ac hie v e d b y diss ol vi n g 0. 1 m g vi al 
of O K -4 3 2 i n 1 0 ml of n or mal sali ne or 0. 1 m g of O K -4 3 2 diss ol ve d i n 5 ml n or mal sali ne . 
T he d ose was n ot b ase d o n lesi o n size.  
Eac h i njecti o n sessi o n w as  perf or me d b y pe diatri c ot olar y n g ol o gists, pe di atric s ur ge o ns, or 
ot her s ur gical s pe cialists wit h c o m para ble e x pertise.  I ntrac ystic fl ui d was as pi[INVESTIGATOR_337] d usi n g a 
2 5 -ga u ge  ( occasi o nall y l ar ger) i ntra ve n o us cat het er. If necess ar y, nee dle pl ace me nt w as 
c o nfir me d b y ultras o n o gra p h y.  F o ll o wi n g as pi[INVESTIGATOR_1313] o n, O K-[ADDRESS_56839]  at t he 
a p pr o priate c o nce ntrati o n . F oll o wi n g i njecti o n, s u bjects were o bser ve d i n t he rec o v er y 
r o o m/ h os pi[INVESTIGATOR_307] f or a p pr o xi matel y ~ 4 h o urs. I n t he a bse nce of s y m pt o ms t hat necessitate 
a d missi o n (i ncl u di n g b ut n ot li mite d t o se psis, s h oc k, air wa y c o m pr o mise, seiz ures), s u bjects 
will be disc har ge d.  
A  [ADDRESS_56840] -tre at me nt Peri o d/ F oll o w u p 
V 1  V 2 ; 
( 1st I nj.) V 3 ; 
[ADDRESS_56841] I nj.  V 4 ; 
( 2n d I nj.) V 5 ; 
( 3r d I nj.) V 6 ; 
( 4t h I nj.) V 7;  
1 -6 m o nt hs after 
Fi n al I nj.  V 8 ; 
1 ye ar after Fi n al 
I nj. 
( O pti o n al) V 9/ St u d y E xit ; 
2 ye ars after Fi n al I nj.  
( O pti o n al) 
I nf or m e d C o nse nt x          
C o m plete Hist or y  x       x    
F oc use d Hist or y   x  x  x  x  x   x  x  
Pe nicilli n Aller g y Testi n g  x          
P h ysical E xa mi nati o n  x  x  x  x  x  x  x  x  x  
Cli nical S ta gi n g1 x         x  
Vital Si g ns   x  x  x  x  x  x  x   
La b orat or y A nal ysis7  x       x    
Pre g na nc y Test4  x          
Me dical P h ot o gra p h y  x       x    
A E/ S A E  x  x  x  x  x  x  x  x  
M RI/ C T6 x       x    
Ass ess me nt Q uesti o n naire2  x   x  x  x     
Dr u g A d mi nistrati o n   x   x  x  x     
S u bject  Diaries3   x   x  x  x     
V –  Visit, I nj. –  I njecti o n 
 
1  Cli nical sta gi n g base d o n m o difie d de Serr es classificati o n . 
2 A n assess me nt f or m wit h a ret ur n e n vel o pe was gi ve n t o patie nt/fa mil y t o fill o ut  3 -5 da ys a n d 2 -3 
wee ks  after eac h i njecti o n series.   
3 S u bjects d oc u me nt e d dail y te m perat ure, pai n, er yt he ma, e de ma, a n d si de effects f or 1 4 da ys after eac h 
i njecti o n sessi o n. 
4 I n fe males of c hil d-beari n g a ge.  
  
5A 4 -d ose i njecti o n series  was pla n ne d f or all s u bjects s pace d a p pr o xi matel y 6 -1 2 wee ks a part . If a 
c o ntrai n dicati o n e xiste d, or a c o m plete res p o nse was o bser ve d pri or t o c o m pleti o n of all 4 i njecti o ns, 
s u bjects wer e treate d wit h fe wer t ha n 4 i njecti o ns. S u bjects  ma y ha ve bee n treate d wit h  m ore t ha n  4 
i njecti o ns if m ulti ple L Ms were treate d or if t here was a rec urre nce. 
6 M RI/ C T ma y ha ve bee n perf or me d at a d diti o nal ti me p oi nts per I n vesti gat or’s discreti o n . 
7 La b orat or y a nal ysis was c o n d ucte d at c o nc urre nt e val uati o ns if it was c o m plete d greater t ha n 3 m o nt hs 
fr o m pre-treat me nt e xa mi nati o n. 
 
  
O K -4 3 2 -0 0 3 -O P E N  Statistical A nal ysis Pla n   
 
1 0  4  S T U D Y E N D P OI N T S  
4. 1  Pri m ar y Effic ac y E n d p oi nt (s) 
T he p ri mar y effic ac y e n d p oi nt is t he pr o p orti o n of s u bjects wit h cli nical s uccess defi ne d as 
ha vi n g eit her a c o m plete or a s u bsta ntial  res p o nse t o t hera p y at [ADDRESS_56842] -t hera p y as 
assesse d b y i ma gi n g ( M RI a n d/ or C T). T he p ost -t hera p y i ma gi n g was d o n e at 1-[ADDRESS_56843] i nj ecti o n series  (if fe w er t ha n f o ur). If s u bjects were treate d wit h m or e 
t ha n [ADDRESS_56844]-treat me nt as assesse d b y i ma gi n g . Ta bl e 2  descri bes t he criteria f or 
assess me nt of cli nical r es p o nse.  
T a ble 2  Res p o nse Assess me nt Criteri a  
C o m plete Res p o nse  9 0 % – 1 0 0 % re d ucti o n i n v ol u me  
S u bsta ntial Res p o nse  6 0 % –  8 9 % re d ucti o n i n v ol u me  
I nter me diate Res p o nse  2 0 % – 5 9 % re d ucti o n i n v ol u me  
N o Res p o nse  < 2 0 % re d ucti o n i n v ol u me  
 
4. 2  Sec o n d ar y Effic ac y E n d p oi nts  
T he sec o n d ar y efficac y e n d p oi nts i ncl u de:  
1.  T he pr o p orti o n of s u bjects w h o de m o nstrate d  c o m plete, s u bsta ntial, i nter me diate, or 
n o res p o nse [ADDRESS_56845] e d as “ C li nical I m pr o ve me nt” or “ N o C ha n ge” . T he e val uati o n was perf or me d 
vis uall y at e ac h i njecti o n series a n d f oll o w u p visits fr o m sec o n d i njecti o n s eries 
o n war ds.  
3.  T he c ha n ge a n d perce nt c ha n ge fr o m b aseli ne i n lesi o n v ol u me fr o m t he i ma gi n g 
data, w here t he bas eli ne v ol u me is defi ne d as t he pre -t hera p y v ol u me. 
4. 3  S afet y E n d p oi nts  
T he safet y e n d p oi nts i ncl u de :  
  Reacti o ns t o O K -4 3 2 i ncl u di n g:  
  
O K -[ADDRESS_56846] -tr eat me nt q uesti o n naire  Case Re p ort F or m 
( C R F). 
o  I n v esti gat or-e v al uate d cli nical reacti o ns t o O K -[ADDRESS_56847] -
treat me nt Cli nical Res p o nse C R F . 
  I n ci de nce of seri o us a d verse e ve nts . 
  Cli nicall y si g nifica nt c ha n ges i n la b orat or y val u es  (c he mistr y, he mat ol o g y, ser ol o g y 
a n d uri nal ysis).  
  P h ysical e x a m.  
  Vital Si g ns.   
[ADDRESS_56848] o ne 
i njecti o n of O K-4 3 2.   
5. 3  M o difie d I nte nt -t o-Tre at  P o p ul ati o n  
T he M o difie d I nte nt -t o-Treat ( mI T T) p o p ulati o n  i ncl u des all E nr olle d s u bj ects t hat ha ve b ee n 
treate d wit h at least o ne i njecti o n of O K -[ADDRESS_56849] u d y w as c o n d ucte d s o t hat s u bjects ma y h a ve c o nti n ue d access 
t o O K-4 3 2  o n a c o m p assi o nate use basis a n d res p o nse data was n ot w ell d oc u me nte d f or 
e ver y o ne, t h e m o difie d I nte nt-t o-Treat p o p ulati o n ( mI T T) p o p ulati o n is defi ne d t o better 
assess t he res p o ns e rate b ase d o n t he o bser ve d dat a.  
[ADDRESS_56850] h a d pri or s ur ger y, a n d wei g ht, hei g ht, a n d B MI at 
baseli ne.  A ge gr o u ps will be s u m mariz e d b y t he f oll o wi n g cat e g ories:  
  < 6 m o nt hs  
  6 m o nt hs t o < 1 8 years  
  6 m o nt hs t o < 2 years  
  2 t o < 6 years  
  6 t o < 1 2 years  
  1 2 t o < 1 8 years  
  1 8 t o < 6 5 years  
  ≥ [ADDRESS_56851] u d y (fr o m 
pre -treat me nt t hr o u g h p ost-treat me nt peri o d). Ne w c o nc o mita nt me dicati o ns i ncl u de all 
me dicati o ns starte d after recei vi n g t he first O K -[ADDRESS_56852] u g Dicti o nar y ( W H O-D D) will be use d t o cate g orize 
ver bati m descri pti o ns of n o n -st u d y me dicati o ns i nt o t he A nat o mic T hera pe utic C he mist r y 
( A T C) classificati o n s yst e m. Eac h ver bati m na me will be classifie d b y a nat o mical mai n 
gr o u p ( A T C le vel 1), t hera pe utic s u b gr o u p ( A T C le vel 2), p har m ac ol o gical s u b gr o u p ( A T C 
le vel 3), c he mical s u b gr o u p ( A TC le vel 4), preferre d ter m, a n d tr a de na m e (if a p pr o priate). 
N u m bers a n d perce nta ges of s u bjects wit h c o nc o mita nt a n d ne w c o nc o mit a nt me dicati o ns 
will be s u m mariz e d b y A T C classificati o n ( A T C l e vel 2 a n d le v el 4) f or t h e Safet y 
p o p ulati o n.   
6. [ADDRESS_56853] greater t ha n t he precisi o n of t he ori gi nal 
val ue. S Ds, S Es, a n d 9 5 % c o nfi de n ce i nter val s ( CIs) will be r o u n de d t o t w o deci mal places 
greater t ha n t he precisi o n of t he ori gi nal val ue. Perce nta ges f or s u m marizi n g cate g orical data 
will be r o u n de d t o t he nearest w h ole n u m ber . 
7. 1. [ADDRESS_56854]-treat me nt, if a p plica ble . Ort h o g o nal meas ure me nts of L M 
siz e o n C T  or M RI  fi n di n gs will be use d t o c alc ulate v ol u me/size. V ol u me will be deri ve d 
fr o m le n gt h × wi dt h × hei g ht if all t he t hree val ues are a v aila ble. If a n y of t he le n gt h, wi dt h, 
or hei g ht d ata are missi n g, t he v ol u me v al ue as r e p orte d will be use d t o deri ve t he res p o nse. 
If v ol u me data is n ot a vaila ble b ut t here is c ollect e d res p o nse dat a, t he n c oll ecte d res p o nse 
data will be use d.   
  
O K -[ADDRESS_56855] se v erit y or te m p erat ur e 
will be use d t o c o nser vati vel y ca pt ure  s afet y d ata.    
O nl y dat a fr o m t he sc h e d ule d visits will be use d f or ta bles, b ut all visits, i ncl u di n g 
u nsc he d ule d visits will be prese nt e d i n listi n gs.  
F or o bser vati o ns fr o m m ulti ple ra di ol o gists, t he a vera ge of t he t w o val u es will be use d f or 
a nal ysis. F or m ultil oc ular v ol u me meas ure m e nts (i.e . res ults fr o m m ulti ple si des of t he sa me 
L M), t he val ues will be a d de d t o get her f or a nal ysis.  
7. 1. [ADDRESS_56856] u d y ( p ost -tr eat me nt 
visits occ urre d at ~ 2 wee ks , 2 4 -2 6 wee ks , 5 0-5 2 wee ks a n d 2 years  after treat me nt). T h e 
p ost -treat me nt efficac y assess me nt was perf or me d at ~ 2 wee ks after treat m e nt. H o we ver, t he 
pr ot oc ol was a me n d e d i n J a n uar y 2 0 1 1, w hic h e x pa n de d t he visit wi n d o w fr o m ~ [ADDRESS_56857] -
treat me nt was ma d e o pti o nal.  
F or t he p ur p os e of a n al ysis, t he ~ [ADDRESS_56858] r ec or d c orres p o n di n g t o t he ~ [ADDRESS_56859]-
treat me nt will be use d i n ta ble s u m maries. B ot h  rec or ds will be pres e nte d i n t he listi n gs wit h 
ass ociate d visi t dates. 
7. 1. 6  H a n dli n g of Missi n g or P a rti al D ates  
I n cases of i nc o m plete dates f or A Es, t he missi n g c o m p o ne nt(s) will be ass u me d as t he m ost 
c o nser vat i ve v al ue(s) p ossi ble. F or e x a m ple, t he i m p utati o n r ule is t o c o nser vati vel y ca pt ure 
A Es wit h missi n g start da tes as treat me nt-e mer ge nt A Es ( T E A Es) . A ct ual data val ues, as 
t he y a p pear i n t he cli nical data base, will be s h o w n i n t he data listi n gs. R ules f or partial dat es 
are des cri be d i n  T a ble [ADDRESS_56860] i nj ecti o n 
  
O K -4 3 2 -0 0 3 -O P E N  Statistical A nal ysis Pla n   
 
1 5  P ar a meter  Missi n g  A d diti o n al C o n diti o ns  I m p ut ati o n 
M a n d/ or Y n ot sa m e as M a n d Y 
of first i nj ecti o n First da y of n o n -missi n g m o nt h  
D a n d M  Y sa me as Y of first i nj ecti o n Date o f first i nj ecti o n 
Y n ot sa me as Y of first i nj ecti o n Use J a n 1 of n o n -missi n g year  
M, D a n d Y  N o ne –  date c o m pletel y missi n g  Date of first i nj ecti o n 
St o p date f or A Es  D o nl y   Last da y of n o n -missi n g m o nt h                                                                                                                    
D a n d M   Use Dec [ADDRESS_56861] u d y 
partici pati o n  
N otes: D = Da y, M = M o nt h, Y = Year  
Start a n d s t o p dates were n ot c ollecte d f or n o n-st u d y me dicati o ns a n d will n ot be i m p ute d. 
Deter mi nati o ns f or n e w c o nc o mita nt me dicati o ns will be  base d o n t he c ollecte d visit date.  
7. 1. 7  H a n dli n g of Missi n g Effic ac y D at a  
I n ge neral, n o i m p utati o n of missi n g efficac y d ata will be perf or me d. T he efficac y data will 
be prese nt e d as o bser ve d.   
7. 2  Effic ac y A n al yse s 
7. 2. 1  A n al yses of Pri m ar y E n d p oi nt(s)  
T he pr o p orti o n of s u bjects wit h cli nical s uccess (a c o m plete or s u bsta ntial  res p o nse) at [ADDRESS_56862] -t hera p y as assesse d b y i ma gi n g will be s u m mariz e d f or t he mI T T p o p ul ati o n.  
7. 2. 1. 1  Se nsiti vit y  A n al ysis  
T he pri mar y a n al ysis will als o be re peate d f or a s u b gr o u p o f t he mI T T p o p ulati o n b y 
e x cl u di n g s u bjects wit h missi n g i nf or me d c o nse nt d oc u me ntati o n. N ote t hat t he i nf or me d 
c o nse nt f or m ( I C F) d o c u me ntati o n f or s o me E nr olle d  s u bjects were n ot retrie va ble fr o m 
st u d y sites f or t his le gac y st u d y. T heref ore, t his se nsitivit y a n al ysis will be perf or me d t o 
e val uate t he r o b ust ness of t he effi cac y res ults o n s u bjects t hat were e nr olle d t o t he st u d y wit h 
a vaila ble I C F d oc u me ntati o n.  
7. 2. [ADDRESS_56863] -T her a p y  as Assesse d b y I m a gi n g  
T he  pr o p orti o n of s u bjects w h o de m o nstrate d a c o m plete (9 0 % – 1 0 0 % re d u cti o n i n v ol u me ), 
s u bsta ntial ( 6 0 %–  8 9 % re d ucti o n i n v ol u me), i nter me diate ( 2 0 % – 5 9 % re d ucti o n i n v ol u me), 
or n o ( < 2 0 % re d ucti o n i n v ol u me) res p o nse [ADDRESS_56864] -t hera p y res p o nse rates vary  i n t he p o p ulati o n b y v ari o us c o vari ates, 
the cate g ori es of res p o nse rates i n s u bjects will als o be s u m marize d b y t he f oll o wi n g 
c o variates: 
  A ge gr o u ps as d e fi ne d i n Secti o n 6. 2 , 
  Se x , 
  Race ( W hite/ N o n -W hite) , 
  Pri or S ur ger y ( Yes/ N o) , 
  L M t y pe ( macr oc ystic, mi x e d, micr oc ystic),  
  C li nical sta ge (cli nical sta ge ta bles will i ncl u de cli nical sta ge m o difier data f or 
me diasi nal i n v ol ve me nt a n d retr o p h ar y n geal i n v ol ve me nt),  
  N u m ber of i njecti o ns r ecei ve d.  
T he  pri mar y e n d p oi nt, pr o p orti o n of cli nical s uccess , will als o be s u m marize d b y t h e a b o ve 
c o variates.  
7. 2. 2. [ADDRESS_56865] u d y will be 
s u m marize d f or t he mI T T p o p ulati o n . I n v esti gat or-e val u ate d O verall res p o nse (eit her 
Cli nical I m pr o ve m e nt or N o C ha n ge) will als o be s u m marize d b y visit (i ncl u di n g a n o v erall 
r o w t hat p o ole d data fr o m all visits ) f or t he m I T T p o p ulati o n. A si milar s u m mar y will be 
pr o d uce d f or o verall res p o nse  as deter mi ne d b y i n vesti gat or j u d ge me nt  b y t he c o vari ates as 
o utli ne d i n Secti o n 7. 2. 2. 1  f or t he mI T T p o p ulati o n.  
I n a d diti o n, t he pr o p orti o n of s u bjects w h o rec or de d “ Cli nical I m pr o ve me nt” o n t he P ost-
t hera p y Cli nical Res p o nse C R F c ollecte d fr o m t he sec o n d i njecti o n visit o n war ds will be 
p o ole d a n d s u m mariz e d ≥ [ADDRESS_56866] -
treat me nt, ≥ [ADDRESS_56867] rec or d of “ Cli nical 
I m pr o v e me nt” o n t he Post -t hera p y Cli nical Res p o nse C R F d uri n g t h e treat me nt peri o d a n d [ADDRESS_56868] i n t h e mI T T 
p o p ulati o n . If s u bjects di d n ot rec or d “ Cli nical I m pr o ve me nt” d uri n g t h ose s pecific treat me nt 
peri o ds, s u bjects will be ce ns ore d at t he last date a vaila ble a m o n g t he i n vesti gat or ass ess me nt 
date, vital si g ns, i njecti o n date, or ter mi nati o n dat e wit hi n t he s pecific p eri o d, w hic he ver is 
t he latest. A d diti o nall y, s u bjects w h o ha d m ore t h a n 4 i njecti o ns will be  ce ns ore d at t he 
f o urt h i njecti o n series if t he y h a ve n ot rec or de d Cli nical I m pr o ve me nt . T he Ka pla n -Mei er 
esti mates a n d t he 9 5 % CIs of t he s ur vi val f u ncti o ns of t he ti me t o o bser ve ‘ Clinical 
I m pr o v e me nt’ will be cal c ulate d.  
7. 2. 4  Ot her A n al ysis  
F or  s u bjects wit h ≥[ADDRESS_56869] u d y 
c o m pleti o n s uc h as n o rec urre n ce, micr oc ystic resi d ue/ resi d ual c yst, rec urre nce, s ur ger y, a n d 
n o res p o nse/c h a n ge will b e s u m mariz e d  f or t he m I T T p o p ul ati o n. 
7. 3  S afet y A n al yses  
7. 3. 1  A d verse E ve nts  
A d verse E v e nts ( A E) f or t his st u d y w as defi n e d as a n y d e viati o n fr o m t he e x pecte d res p o nse 
t o O K-[ADDRESS_56870] 
i njecti o n a n d were assess e d b y visit, ti me p oi nt, a n d se verit y (f or l ocal r eacti o ns a n d si de 
effects). P ost -treat me nt Q uesti o n naires w ere c om plete d [ADDRESS_56871] i njecti o n, 3 – [ADDRESS_56872] i njecti o n, a n d 2 – [ADDRESS_56873] i njecti o n via a cli nic visit or safet y p h o n e call, a n d w ere 
assesse d b y visit, ti me p oi nt, a n d se ver it y (f or l o cal reacti o ns). P ost-t hera p y Cli nical 
  
O K -[ADDRESS_56874]-stre pt oc occal gl o mer ul o ne p hritis an d a n assess me nt of J o nes Criteria f or t he 
dia g n osis of a n i nitial attac k of R he u matic Fe v er.  
T he f oll o wi n g O K -4 3 2 reacti o n s u m maries will b e prese nt e d f or t he Safet y p o p ulati o n:  
- Reacti o ns re p ort e d t hr o u g h S u bject  Diar y b y reacti o n cate g or y, ver bati m ter ms, 
visit/ti me p oi nt, se verit y (f or l ocal r eacti o ns a n d si de effects) . 
- Te m perat ur e (c ollecte d via S u bject  Diar y) will be s u m marize d a n d t otal as (a) n u m ber 
a n d perce nt of s u bjects wit h at least 3 8° C ( 1 0 0. 4° F), a n d ( b ) n u m b er a n d p erce nt of 
s u bjects wit h at least 4 0° C ( 1 0 4° F). Fe ver will be defi ne d as a b o d y te m perat ure of at 
least 3 8° C. 
- Reacti o ns re p ort e d t hr o u g h q uesti o n nair e  ( P ost-Treat me nt Q uesti o n nair e C R F)  b y 
reacti o n cate g or y, v er bati m ter ms, visit/ti me p oi nt, sev erit y (f or l o cal r eacti o ns) . 
- I n v esti gat or-e v al uate d reacti o ns ( Cli nical Res p o nse C R F) t o O K -4 3 2 b y reacti o n 
cate g or y, v er bati m ter ms, visit.  
- J o nes Criteria f or t he Dia g n osis of a n I nitial Attac k of R he u matic Fe ver ( Cli nical 
Res p o nse C R F) b y maj or/ mi n or ma nifestat i o ns, visit/ti me p oi nt; Assess me nt of 
He mat uria t o assess p ost -stre pt oc occal gl o mer ul o n e p hritis. 
A listi n g will be pr o vi de d f or t he i nf or mati o n r e p orte d t hr o u g h t he s u bject st u d y diar y, 
q uesti o n naires,  a n d cli nic al res p o nse C R Fs .  
A d diti o nall y, t h e reacti o ns re p orte d t hr o u g h S u bj ect  Diar y, P ost -Treat me nt Q uesti o n naire 
C R F a n d Cli nical Res p o nse C R F will be s u m mariz e d f or t he s u b gr o u p of s u bjects wit h n o n -
missi n g i nf or me d c o nse nt dates si milar t o t he pri mar y effi cac y a nal ysis.  
Ti me t o E v e nt A n al ysis  
T he ti me fr o m first pai n t o res ol uti o n a n d ti me fr o m first fe ver t o res ol uti o n will be c o m p ute d 
f or eac h s u bject at eac h i njecti o n. T he first da y of pai n after a s pecific i njecti o n will be 
defi ne d as t he first diar y re p ort of pai n o n or after t he i njecti o n  da y. T he first da y of fe ver a n d 
t he ti me t o fe ver res ol uti o n will be defi ne d si milarl y usi n g te m perat ure c ollecte d i n t he diar y 
data.  If s u bjects di d n ot rec or d fe ver/ p ai n res ol uti o n d uri n g t he s p ecifie d ti me  peri o d (i.e. 
wit hi n 1 4 da ys after i njecti o n) , t he y will be ce ns or e d at t he last a vaila bl e date of diar y re p ort 
of fe ver/ pai n.  T he K a pla n -Meier esti mates a n d t he 9 5 % c o nfi d e nce i nter vals of t he s ur vi val 
f u ncti o ns of pai n a n d fe v er will be cal c ulate d a n d pl otte d b y  i njecti o n.  
  
O K -4 3 2 -0 0 3 -O P E N  Statistical A nal ysis Pla n   
 
1 9  7. 3. 1. 2  Seri o us A d verse E ve nts  
A Es  were  referre d t o as “ Seri o us A d verse E v e nts” ( S A Es) i n t he st u d y C R F. F or t he 
p ur p oses of t he retr os pecti ve a nal ysis, tr eat me nt -e mer ge nt seri o us a d v erse e ve nts ( T E S A Es) 
are defi ne d as S A Es t hat occ ur after t he first i njecti o n a n d wit hi n [ADDRESS_56875] u d y disc o nti n uati o n will be s u m marize d b y S yste m 
Or ga n Class  ( S O C) a n d Preferre d Ter m  ( P T). 
7. 3. 2  Cli nic al L a b or at or y E v al u ati o ns  
All he mat ol o g y, c h e mistr y,  uri nal ysis a n d s er ol o g y res ults will be s u m marize d f or t he Safet y 
p o p ulati o n , i ncl u di n g dat a fr o m t he sc h e d ule d ass ess me nts . La b orat or y v al ues c ollecte d fr o m 
u nsc he d ule d  visits will be pr o vi de d i n listi n gs o nl y.  La b orat or y assess me nts t hat are o utsi de 
of n or mal ra n ges a n d/ or wit h p ote ntial cli nical si g nifica nce will be c o nsi dere d a n a b n or mal 
val ue a n d fla g ge d i n t he listi n gs. N ote t hat d ue t o l ac k of a ce ntr al la bs n or mal ra n ges are 
differe nt acr oss sites. T h eref ore, s hift ta bles b ase d o n refere nce n or mal r a n ges  will be use d .   
Baseli ne v al ues, t he val u es at p ost -baseli ne visits, a n d c ha n ges fr o m t he bas eli ne val ues will 
be s u m mariz e d descri pti vel y f or all la b orat or y para meters wit h n u merical meas ures. 
A d diti o nall y, s hift ta bles will be ge n erat e d t o s u m marize t he n or mal a n d a b n or mal (a b n or mal 
hi g h a n d a b n or mal l o w) stat us c ha n ges fr o m baseli ne t o p ost -baseli ne visits. T he fre q u e nc y 
a n d perce nta ge of s u bjects wit h la b orat or y res ults a b o ve or bel o w t he n or m al ra n ge at eac h 
sc he d ule d ass ess me nt or a n y ti me d uri n g t he treat me nt will be s u m mariz e d.  
T he f oll o wi n g l a b tests will be s u m marize d: 
  
O K -[ADDRESS_56876] C ate g or y  
C he mistr y  He m at ol o g y  Uri n al ysis  
  Ala ni ne 
A mi n otra nsferase  
  Al b u mi n  
  Al kali ne P h os p hatase  
  As partate 
A mi n otra nsferase  
  Bilir u bi n  
  C Reacti ve Pr otei n  
  Calci u m  
  Car b o n Di o xi de  
  C hl ori de  
  Creati ni ne  
  Gl o b uli n  
  Gl uc ose  
  P otassi u m  
  Pr otei n  
  S o di u m  
  Urea Nitr o ge n    B as o p hils  
  E osi n o p hils  
  Er y. Mea n C or p usc ular 
H G B C o nce ntrati o n  
  Er y. Mea n C or p usc ular 
He m o gl o bi n  
  Er y. Mea n C or p usc ular 
V ol u me  
  Er yt hr oc yte Se di me ntati o n  
Rate  
  Er yt hr oc ytes  
  Er yt hr oc ytes Distri b uti o n 
Wi dt h  
  He mat ocrit  
  He m o gl o bi n  
  Le u k oc ytes  
  L y m p h oc ytes  
  Mea n Platelet V ol u me  
  M o n oc ytes  
  Ne utr o p hils  
  Ne utr o p hils B a n d F or m  
  Platelets  
   B acteria  
  Bilir u bi n  
  Casts  
  C ol or  
  Cr ystals  
  E pit helial Cells  
  Er yt hr oc ytes  
  Gl uc ose  
  Ket o nes  
  Le u k oc yte Esterase  
  Le u k oc ytes  
  M uc us  
  Nitrite  
  Occ ult Bl o o d  
  Pr otei n  
  S pecific Gra vit y  
  T ur bi dit y  
  Ur o bili n o ge n  
  V ol u me  
  p H  
 
Ser ol o g y  
  Stre pt ol ysi n O A nti b o d y  
7. 3. 3  Electr oc a r di o gr a m  
Alt h o u g h Electr ocar di o gra m ( E C G) w as n ot i ncl u de d i n t he a me n de d pr ot oc ol  after J a n uar y 
[ADDRESS_56877] le vel data will be pr o vi de d  i n a 
listi n g. 
7. 3. 4  P h ysic al E x a mi n ati o n  
T he  res ults of p h ysical e x a mi nati o n i ncl u di n g t he f oc use d p h ysic al e x a m will be pr o vi de d i n 
a listi n g.  
7. 3. 5  Vit al Si g ns  
V ital si g ns (te m perat ure, s yst olic a n d diast olic bl o o d press ure, h eart rate, a n d res pi[INVESTIGATOR_1313] o n rat e) 
a n d wei g ht , a n d its c ha n ge fr o m baseli ne, will be s u m marize d descri pti vel y.  
  
O K -4 3 2 -0 0 3 -O P E N  Statistical A nal ysis Pla n   
 
2 1  8  S T A TI S TI C A L S O F T W A R E  
All a nal ys es will be perf or me d wit h S A S® versi o n 9. 4.  